Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver

Laura Falasca, Giuseppe Tisone, Giampiero Palmieri, Alessandro Anselmo, Daniele Di Paolo, Leonardo Baiocchi, Elena Torri, Giuseppe Orlando, Carlo Umberto Casciani, Mario Angelico

Research output: Contribution to journalArticle

Abstract

Background. Ischemia-reperfusion injury is a major cause of early graft dysfunction after liver transplantation. Tauroursodeoxycholic acid (TUDCA), a natural amidated hydrophilic bile salt, protects from cholestasis and hepatocellular damage in a variety of experimental models, as well as from ischemia-reperfusion injury. We investigated in the human liver transplantation setting the effect of the addition of TUDCA at time of liver harvesting and cold storage on the intra- and postoperative enzyme release and liver histopathology at the end of cold storage, at reperfusion, and 7 days after transplantation. Methods. Eighteen patients undergoing elective liver transplantation were studied, including 6 serving as controls. In six patients, TUDCA was added to the University of Wisconsin solution used during harvesting and cold storage, to reach final concentrations of 2 mM. In three of these patients, TUDCA (3 g) was infused in the portal vein of the donor before organ explantation; in the other three cases, TUDCA was given through both routes. Results. The use of TUDCA did not cause adverse events. The release of aspartate aminotransferase in the inferior vena cava blood during liver flushing was significantly lower (P=0.05) in TUDCA-treated than in control grafts, as were cytolytic enzyme levels in peripheral blood during the first postoperative week (P

Original languageEnglish
Pages (from-to)1268-1276
Number of pages9
JournalTransplantation
Volume71
Issue number9
Publication statusPublished - May 15 2001

Fingerprint

Liver
Liver Transplantation
Reperfusion Injury
Transplants
Cholestasis
Inferior Vena Cava
Enzymes
Aspartate Aminotransferases
Portal Vein
tauroursodeoxycholic acid
Bile Acids and Salts
Reperfusion
Theoretical Models
Transplantation
Tissue Donors

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Falasca, L., Tisone, G., Palmieri, G., Anselmo, A., Di Paolo, D., Baiocchi, L., ... Angelico, M. (2001). Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver. Transplantation, 71(9), 1268-1276.

Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver. / Falasca, Laura; Tisone, Giuseppe; Palmieri, Giampiero; Anselmo, Alessandro; Di Paolo, Daniele; Baiocchi, Leonardo; Torri, Elena; Orlando, Giuseppe; Casciani, Carlo Umberto; Angelico, Mario.

In: Transplantation, Vol. 71, No. 9, 15.05.2001, p. 1268-1276.

Research output: Contribution to journalArticle

Falasca, L, Tisone, G, Palmieri, G, Anselmo, A, Di Paolo, D, Baiocchi, L, Torri, E, Orlando, G, Casciani, CU & Angelico, M 2001, 'Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver', Transplantation, vol. 71, no. 9, pp. 1268-1276.
Falasca L, Tisone G, Palmieri G, Anselmo A, Di Paolo D, Baiocchi L et al. Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver. Transplantation. 2001 May 15;71(9):1268-1276.
Falasca, Laura ; Tisone, Giuseppe ; Palmieri, Giampiero ; Anselmo, Alessandro ; Di Paolo, Daniele ; Baiocchi, Leonardo ; Torri, Elena ; Orlando, Giuseppe ; Casciani, Carlo Umberto ; Angelico, Mario. / Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver. In: Transplantation. 2001 ; Vol. 71, No. 9. pp. 1268-1276.
@article{a1d4c54163564cdab932c306fa606c1b,
title = "Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver",
abstract = "Background. Ischemia-reperfusion injury is a major cause of early graft dysfunction after liver transplantation. Tauroursodeoxycholic acid (TUDCA), a natural amidated hydrophilic bile salt, protects from cholestasis and hepatocellular damage in a variety of experimental models, as well as from ischemia-reperfusion injury. We investigated in the human liver transplantation setting the effect of the addition of TUDCA at time of liver harvesting and cold storage on the intra- and postoperative enzyme release and liver histopathology at the end of cold storage, at reperfusion, and 7 days after transplantation. Methods. Eighteen patients undergoing elective liver transplantation were studied, including 6 serving as controls. In six patients, TUDCA was added to the University of Wisconsin solution used during harvesting and cold storage, to reach final concentrations of 2 mM. In three of these patients, TUDCA (3 g) was infused in the portal vein of the donor before organ explantation; in the other three cases, TUDCA was given through both routes. Results. The use of TUDCA did not cause adverse events. The release of aspartate aminotransferase in the inferior vena cava blood during liver flushing was significantly lower (P=0.05) in TUDCA-treated than in control grafts, as were cytolytic enzyme levels in peripheral blood during the first postoperative week (P",
author = "Laura Falasca and Giuseppe Tisone and Giampiero Palmieri and Alessandro Anselmo and {Di Paolo}, Daniele and Leonardo Baiocchi and Elena Torri and Giuseppe Orlando and Casciani, {Carlo Umberto} and Mario Angelico",
year = "2001",
month = "5",
day = "15",
language = "English",
volume = "71",
pages = "1268--1276",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver

AU - Falasca, Laura

AU - Tisone, Giuseppe

AU - Palmieri, Giampiero

AU - Anselmo, Alessandro

AU - Di Paolo, Daniele

AU - Baiocchi, Leonardo

AU - Torri, Elena

AU - Orlando, Giuseppe

AU - Casciani, Carlo Umberto

AU - Angelico, Mario

PY - 2001/5/15

Y1 - 2001/5/15

N2 - Background. Ischemia-reperfusion injury is a major cause of early graft dysfunction after liver transplantation. Tauroursodeoxycholic acid (TUDCA), a natural amidated hydrophilic bile salt, protects from cholestasis and hepatocellular damage in a variety of experimental models, as well as from ischemia-reperfusion injury. We investigated in the human liver transplantation setting the effect of the addition of TUDCA at time of liver harvesting and cold storage on the intra- and postoperative enzyme release and liver histopathology at the end of cold storage, at reperfusion, and 7 days after transplantation. Methods. Eighteen patients undergoing elective liver transplantation were studied, including 6 serving as controls. In six patients, TUDCA was added to the University of Wisconsin solution used during harvesting and cold storage, to reach final concentrations of 2 mM. In three of these patients, TUDCA (3 g) was infused in the portal vein of the donor before organ explantation; in the other three cases, TUDCA was given through both routes. Results. The use of TUDCA did not cause adverse events. The release of aspartate aminotransferase in the inferior vena cava blood during liver flushing was significantly lower (P=0.05) in TUDCA-treated than in control grafts, as were cytolytic enzyme levels in peripheral blood during the first postoperative week (P

AB - Background. Ischemia-reperfusion injury is a major cause of early graft dysfunction after liver transplantation. Tauroursodeoxycholic acid (TUDCA), a natural amidated hydrophilic bile salt, protects from cholestasis and hepatocellular damage in a variety of experimental models, as well as from ischemia-reperfusion injury. We investigated in the human liver transplantation setting the effect of the addition of TUDCA at time of liver harvesting and cold storage on the intra- and postoperative enzyme release and liver histopathology at the end of cold storage, at reperfusion, and 7 days after transplantation. Methods. Eighteen patients undergoing elective liver transplantation were studied, including 6 serving as controls. In six patients, TUDCA was added to the University of Wisconsin solution used during harvesting and cold storage, to reach final concentrations of 2 mM. In three of these patients, TUDCA (3 g) was infused in the portal vein of the donor before organ explantation; in the other three cases, TUDCA was given through both routes. Results. The use of TUDCA did not cause adverse events. The release of aspartate aminotransferase in the inferior vena cava blood during liver flushing was significantly lower (P=0.05) in TUDCA-treated than in control grafts, as were cytolytic enzyme levels in peripheral blood during the first postoperative week (P

UR - http://www.scopus.com/inward/record.url?scp=0035872758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035872758&partnerID=8YFLogxK

M3 - Article

C2 - 11397961

AN - SCOPUS:0035872758

VL - 71

SP - 1268

EP - 1276

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 9

ER -